NCT07444918 2026-03-03
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
Clinical Trials
9 trialsNCT01356290 2026-02-23
MEMMAT
Medical University of Vienna
Phase 2 Recruiting
NCT05629702 2026-01-30
ARISTOCRAT
University of Birmingham
Phase 2 Recruiting
NCT02330991 2023-07-24
A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse
Beijing Sanbo Brain Hospital
Phase 2 Completed
NCT00528437 2021-07-08
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU Langone Health
Phase 2 Completed
NCT01235793 2018-11-20
DRBEAT
Cedars-Sinai Medical Center
Phase 2 Terminated
NCT01517776 2015-07-21
HGG-CilMetro
Martin-Luther-Universität Halle-Wittenberg
Phase 2 Terminated
NCT01193140 2012-11-21
To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
Abbott
Phase 2 Completed
NCT00521482 2007-08-28
Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma
University of Zurich
Phase 2 Unknown